Thus the University of Birmingham is trying to defend the move, which was heavily criticized by the British government in December, when the time between the two vaccinations in the UK was increased to 12 weeks in December to allow as many people as possible to receive their first vaccination from a limited stock of vaccines.
The university studied 172 people between the ages of 80 and 99 who had already received both vaccinations from Pfizer. Of these, 73 used a 12-week period and 99 received a second dose 3 weeks after the first vaccination. At 2-3 weeks after the second vaccination, the highest antibody levels were approximately 3.5 times higher on average in the group receiving the second vaccination for 12 weeks compared to the group receiving 3 weeks between the two doses.
The university professor said that the study may be important to the global vaccination strategy, as it may reduce the need for new vaccines in the elderly. Although it has not yet been possible to say in this case a vaccine may provide protection.
Cellular immunity was also examined in the study, but no significant difference was found between those vaccinated with a difference of 12 weeks and 3 weeks. In the group inoculated with a difference of 3 weeks, the T-cell immune response developed faster and reached a higher value, but it also began to decline rapidly. After 15 weeks, very similar values were measured in both groups.
The researchers promised that people who were tested in the studies would be monitored for another 6 months.
Cover photo: Getty Images
“Social media evangelist. Baconaholic. Devoted reader. Twitter scholar. Avid coffee trailblazer.”